Vor Bio appoints Dallan Murray as chief commercial officer, leveraging his extensive experience to drive commercialization ...

The journal is standing by the study, which looked into the safety of vaccines that have aluminum ingredients.

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab ...

A new CDC campaign "Free Mind" addresses rising drug overdoses and mental health issues among youth, offering vital resources ...

Accelerated approval was based on results from the Phase Ib Beamion-LUNG 1 trial (NCT04886804), which showed a 75% objective ...

Today, imaging often exists independently of molecular insights, trial data, treatment decisions, and longitudinal patient ...

Vinay Prasad, MD, MPH, who was appointed to run the FDA's Center for Biologics Evaluation and Research (CBER) in May, then ...

Results from the Phase III CONVOKE trial (NCT05838625) showed that CT-155 demonstrated a favorable safety profile consistent ...

Radella Pharmaceuticals reveals promising Phase 1b trial results for MD-18, showcasing significant weight loss and ...

GLP-1 medication users must consult physicians before surgery to mitigate anesthesia risks and ensure safe pre-operative ...

Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one ...

Chai Discovery secures $70 million to revolutionize AI-driven drug discovery, enhancing antibody design and accelerating ...